Research Reports

Key takeaways

CFO Eric Hyllengren was separated from the Company on April 20, 2026, for reasons unrelated to financial results or disagreements.

Marlyn Mathew, Vice President of Finance and Accounting, was appointed as Principal Financial and Accounting Officer effective April 20, 2026.

Ms. Mathew received an approved annual base salary increase to $366,415 in connection with her new appointment.

Mr. Hyllengren's separation agreement includes severance equal to three months of base salary and six months of COBRA reimbursement.

The separation agreement includes a waiver of the Company's right to reclaim approximately $15,000 in airline travel credits held in Mr. Hyllengren's name.

Full analysis

Zura Bio Limited executed a transition of its principal financial officers on April 20, 2026. Eric Hyllengren departed his role as Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer. The filing explicitly states the separation was not related to the Company's financial results, operating results, or any disagreements regarding operations or reporting practices, which mitigates typical investor concerns regarding abrupt executive departures. Concurrent with the departure, the Board appointed Marlyn Mathew, who has served as Vice President, Finance and Accounting since June 2022, to the roles of Principal Financial and Accounting Officer. Ms. Mathew's prior experience includes serving as Controller at Immunovant. Her compensation was adjusted to an annual base salary of $366,415. The Separation Agreement filed as Exhibit 10.1 details standard transition terms for Mr. Hyllengren, including salary continuation and COBRA benefits, alongside a specific waiver regarding $15,000 in airline travel credits.

ZURA · Zura Bio Limited

Summary

Key takeaways

Full analysis